RVTY Revvity
Q1 2025 10-Q
Revvity (RVTY) 10-Q quarterly report for Q1 2025, filed with SEC EDGAR on May 6, 2025 for the fiscal period ending Mar 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AI Filing AnalysisQ1 2025 10-Q
Management Discussion & Analysis
- • Revenue $664.8M, up 2% YoY from $649.9M; Life Sciences $340.4M (+1%), Diagnostics $324.4M (+3%)
- • Gross margin 56.5% vs 54.6% YoY; SG&A margin 37.6% vs 40.1% YoY; R&D margin 8.1% vs 7.7% YoY
Risk Factors
- • New risk: Cautious customer spending due to recent and proposed U.S. funding and regulatory uncertainties impacting government and industrial funding approvals
- • Most materially updated risk: Increased supply chain risks from global conflicts and tariffs, including Ukraine war and retaliatory trade measures affecting costs and delivery
Quarterly Financial SummaryXBRL
Revenue
$665M
▲ +2.3% YoY
Net Income
$42M
▲ +62.4% YoY
Net Margin
6.4%
▲ +235bp YoY
Source: XBRL data from Revvity Q1 2025 10-Q filing on SEC EDGAR. All figures in USD.
Other Revvity Quarterly Reports
Get deeper insights on Revvity
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.